The efficacy of adeno-associated virus (AAV)-mediated gene therapy for the inner ear is fundamentally constrained by the natural tropism of viral vectors, which often lack the precision and efficiency required to robustly target specific sensory cell populations, such as hair cells, without high-dose or invasive delivery. Engineering capsids to overcome this barrier is therefore a critical frontier in developing viable treatments.
This study, published in ENT Discovery, details a rational design approach where researchers screened and inserted short peptide motifs onto the surface of the AAV1 capsid. The work by Yunqing Wang and colleagues demonstrates that these engineered vectors, when administered locally in preclinical models, achieved markedly higher transduction rates in inner ear hair cells and supporting cells compared to the parental AAV1 serotype. The selected peptides appear to facilitate improved cellular binding and internalization, effectively redirecting the vector's natural targeting profile. This enhanced tropism could lower the required therapeutic dose, potentially reducing off-target effects and immune risks.
The successful development of these targeted vectors represents a significant leap in tool design for both basic research and therapeutic applications. It opens the door to more effective gene replacement, gene editing, and neurotrophic factor delivery strategies for a wide array of cochlear and vestibular pathologies. However, translating these findings requires thorough investigation into the long-term safety and expression stability of the modified vectors, as well as assessment of their performance in models of human disease. Scaling up production for clinical use and navigating potential new immune responses to the engineered capsid present additional future hurdles. This work, entitled "Enhanced Inner Ear Tropism of Adeno-Associated Virus (AAV) Vectors via Peptide Display on AAV1 Capsid" was published on ENT Discovery (published on Dec. 31, 2025).
